Esperion Therapeutics, Inc. 8-K

What Happened
Esperion Therapeutics, Inc. (filed Form 8‑K on June 9, 2026) reiterated that it entered into a Merger Agreement on May 1, 2026 with Essence Parent Inc. (an affiliate of ArchiMed SAS) and Essence MergerCo Inc. Under the deal, MergerCo would merge into Esperion, leaving Esperion as a wholly‑owned subsidiary of Parent if the transaction closes. The company received notice on June 8, 2026 that the Bundeskartellamt (German antitrust authority) cleared the Merger effective June 2, 2026.

Key Details

• Merger Agreement signed: May 1, 2026.
• German antitrust clearance: Bundeskartellamt notice received June 8, 2026 (effective June 2, 2026).
• Remaining closing conditions include expiration/termination of U.S. HSR waiting periods and adoption of the Merger Agreement by Esperion stockholders.
• Special meeting to vote on the merger: scheduled virtually for July 8, 2026 at 8:00 a.m. Eastern Time.
• Proxy Statement (Schedule 14A) has been filed and mailed to stockholders; the filing highlights forward‑looking statements and risks, including that contingent payments under CVRs depend on net sales milestones.

Why It Matters
The Bundeskartellamt clearance removes a key European regulatory hurdle, but the transaction is not complete—U.S. antitrust clearance (Hart‑Scott‑Rodino waiting periods) and shareholder approval are still required. If the Merger closes, Esperion would become a wholly‑owned subsidiary of Parent, which could materially change the company’s public status and governance. Retail investors should review the Proxy Statement and SEC filings for full terms, the timeline, voting instructions, and the risks (including that contingent CVR payments are tied to future net sales milestones). Copies of the Proxy and other materials are available free on EDGAR (www.sec.gov) and on Esperion’s investor relations page.